Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis BD400
- Development stage
- Preclinical
- Lead developer
- Bright Dairy
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis BD400 is a probiotic strain developed by Bright Dairy & Food Co., Ltd. for the prevention and treatment of rheumatoid arthritis (RA). It functions as a microbiome therapy that restores intestinal microbiota homeostasis and strengthens the intestinal mucosal barrier by up-regulating tight junction proteins such as occludin-1, MUC-2, and ZO-1. In preclinical models of collagen-induced arthritis (CIA), oral administration of BD400 significantly reduced arthritis clinical scores, paw swelling, and joint damage. The therapeutic effect is mediated through the down-regulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-17A) and the modulation of the histidine metabolic pathway, specifically reducing levels of 1-methyl-L-histidine and urocanate.
- Other names
- B. animalis BD400
02
Targets
IL-17A (Interleukin-17A)IL1B (Interleukin-1 beta)OCLN (Occludin)TNFA (Tumor necrosis factor alpha (soluble))TJP1 (Tight junction protein 1 (ZO-1))
Beyond the preview
Go deeper on Bifidobacterium animalis BD400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis BD400.